Histone deacetylase (HDAC) inhibitor
Givinostat
Brand names: Duvyzat
Adult dose
Dose: Weight-based PO BD with food — refer to BNF/SmPC
Route: PO
Frequency: BD
Clinical pearls
- Duchenne muscular dystrophy in patients ≥6 yrs; specialist neuromuscular service
Contraindications
- Pregnancy
- Concurrent QT-prolonging drugs
Side effects
- Diarrhoea
- Thrombocytopenia
- Hypertriglyceridaemia
- QT prolongation
Interactions
- QT-prolonging drugs
- Strong CYP3A4 modulators
Monitoring
- FBC
- Lipids
- ECG
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/givinostat/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS